Position in AKBA
as of Mar 31, 2026
· filed Apr 27, 2026
Position Value
$204,481
-$92,853 QoQ
Shares Held
147,109
-20.3% QoQ
Ownership
0.053%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026PROFUND ADVISORS LLC holds $16,960,434 across 29 Drug Manufacturers - Specialty & Generic names. AKBA ranks #25 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
4,687 | $2,779,297 | |
| 2 | ALKS |
Alkermes plc.
|
77,769 | $2,749,911 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
17,687 | $2,330,085 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
158,462 | $1,508,558 | |
| 5 | ZTS |
Zoetis Inc.
|
6,653 | $786,451 | |
| 6 | ELAN |
Elanco Animal Health Inc
|
22,305 | $533,758 | |
| 7 | HLN |
Haleon plc
|
50,589 | $506,395 | |
| 8 | VTRS |
Viatris Inc
|
29,453 | $397,910 |
All Filings in AKBA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $204,481 | 147,109 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $297,334 | 184,680 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $283,849 | 103,974 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $200,425 | 55,062 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $86,250 | 44,922 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $71,573 | 37,670 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||